What did @asianlink actually say?
The creator says they felt hungrier after starting Retatrutide ("Retta") and texted their doctor for an explanation. Their doctor's theory: a lifelong slow metabolism is now being "sped up" by the drug, and that acceleration is driving the hunger. The creator then asks, openly, whether this explanation holds water or whether they're just rationalizing an uncomfortable side effect.
Credit where it's due: they framed it as a question, not a declaration. "Am I coping or can that be possible?" is a more honest framing than most TikTok peptide content manages. Still, the explanation their doctor offered deserves scrutiny, because it conflates two very different physiological processes.
Does the science back this up?
Not really, at least not in the way the doctor described it. Retatrutide is a triple agonist, hitting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component is where this gets interesting. Glucagon does increase energy expenditure and can raise basal metabolic rate, which is measurable in trials. But "speeding up metabolism" causing hunger is largely backwards from how GLP-1 class drugs actually work.
In the Phase 2 trial by Jastreboff et al. (2023, NEJM), Retatrutide produced substantial weight loss, primarily because the GLP-1 and GIP components suppress appetite and slow gastric emptying. Increased hunger is not a listed primary mechanism. If anything, the drug is engineered to do the opposite. Glucagon receptor agonism does increase thermogenesis, but elevated metabolic rate does not reliably translate into acute hunger signals in the literature. The hunger-metabolism link the doctor described is more folk physiology than established endocrinology.
What did they get wrong (or right)?
The creator got something right by reporting their actual lived experience without dressing it up. Increased appetite as a side effect, particularly early in treatment or at lower doses, is plausible. Dose titration with GLP-1 receptor agonists affects appetite suppression variability. Some users report a window where appetite suppression hasn't fully engaged.
What's less defensible is the doctor's specific mechanism: that a lifetime of slow metabolism is now being "sped up" and that this is directly causing hunger. There's no peer-reviewed evidence connecting Retatrutide's glucagon-mediated thermogenesis to an increase in hunger signals in this population. The explanation is speculative at best. Metabolic rate and appetite regulation are related but not linearly linked, and framing it as a simple "faster metabolism equals more hunger" equation oversimplifies the GLP-1/GIP/glucagon interplay considerably. This is a case where the doctor may have offered a comforting narrative rather than a mechanistically accurate one.
What should you actually know?
Retatrutide is still investigational. It is not FDA-approved as of mid-2025. Any use outside of a clinical trial happens in a regulatory gray zone, and compounded versions carry additional quality and dosing uncertainties that brand-name approved drugs do not. If you're experiencing unexpected side effects like increased hunger, that's worth documenting and reporting to your prescriber, not just texting about once.
Appetite changes early in GLP-1 class therapy are real and documented. Blüher et al. (2021, Nature Reviews Endocrinology) notes that individual response variability to GLP-1 receptor agonists is significant and not fully understood. If someone is genuinely experiencing increased hunger, the more likely explanations include subtherapeutic dosing, injection timing, or individual receptor sensitivity, not a metabolism-acceleration cascade. Anyone self-monitoring on these compounds should track symptoms systematically, not rely on single-text consultations for mechanistic explanations.
Is there any context that changes the picture?
One thing worth noting: glucagon receptor agonism does have documented appetite-modulating effects that are still being characterized. Finan et al. (2015, Nature Medicine) showed in animal models that glucagon co-agonism affects both thermogenesis and food intake in complex ways. Human data on Retatrutide specifically is still limited to early-phase trials. So while the doctor's explanation is not well-supported, the honest answer is that Retatrutide's full appetite profile in diverse human populations is not yet fully mapped. The creator's experience may be real even if the explanation offered for it is incomplete.